Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Phenylketonuria

In brief

SYNB1934-CP-003 was designed as a 3-part, adaptive study consisting of a dose-escalating, open-label period (DEP; Part 1) of up to 15 weeks, followed by a 4-week, double-blind, placebo-controlled, randomized withdrawal period (RWP; Part 2), and an open-label extension (OLE; Part 3) of up to 36 months

Key facts

Study ID

NCT05764239

Run by

Synlogic

People needed

35

Starts

2023-07-05

Expected to finish

2024-03-15

Last updated by the study team

2024-06-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years.
• Able and willing to voluntarily complete the informed consent process.
• Diagnosis of phenylketonuria (PKU) and failure to maintain recommended blood Phe levels on existing management (sapropterin, sepiapterin, and/or Phe-restricted diet), demonstrated by uncontrolled blood Phe level > 360 μmol/L on current therapy any time during screening and uncontrolled blood Phe level > 360 μmol/L on current therapy when taking the average of the 3 most recent Phe levels from the participant's medical history (inclusive of any screening values). All screening values must have been obtained more than 7 days apart, as determined by central or local laboratory.
• Females of childbearing potential must have had a negative pregnancy test at screening and at the end of the DEP (in order to enter the RWP) and RWP (in order to enter the OLE) and been willing to have additional pregnancy tests during the study.
• Sexually active female participants of childbearing potential must have been willing to use an acceptable method of contraception while participating in the study and for 2 weeks after the last dose.
• Stable diet including stable medical formula regimen (if used) for at least 1 month prior to screening.
• If using sapropterin or sepiapterin, must have been on a stable dose for at least 3 months.
• Willing and able to continue current diet, sapropterin, sepiapterin, and large neutral amino acids unchanged during screening, DEP, and RWP and to engage in all study activities.

You may not qualify if…

• Currently taking Palynziq® (pegvaliase-pqpz) (within 1 month of screening).
• Acute or chronic medical, surgical, psychiatric, or social condition or laboratory abnormality that may have increased participant risk associated with study participation, compromised adherence to study procedures and requirements, and, in the judgment of the investigator, would have made the participant inappropriate for enrollment.
• A known or suspected diagnosis of DNAJC12 deficiency, biopterin synthesis deficiency, or irritable bowel syndrome.
• Intolerance to or allergic reaction to Escherichia coli Nissle or any of the ingredients in SYNB1934v1 formulation, or an allergy to cinnamon. Known intolerance to proton pump inhibitors and H2 blockers, since one or the other must have been used.
• Currently taking or plans to take any type of systemic (e.g., oral or intravenous) antibiotic within 28 days prior to the first dose of SYNB1934v1 through final safety assessment in the RWP, including planned surgery, hospitalizations, dental procedures, or interventional studies that were expected to require antibiotics. Exception: topical antibiotics were allowed.
• Pregnant, planning to become pregnant, or breastfeeding.
• Current participation in any other investigational drug study or use of any investigational agent within 30 days or 5 half-lives (whichever was longer) prior to screening.
• Ever received gene therapy for treatment of PKU.

Where it is running

• Science 37 — Culver City, California, United States
• Children's Hospital Orange County — Orange, California, United States
• Stanford University, Department of Pediatrics — Palo Alto, California, United States
• University of Colorado Children's Hospital — Aurora, Colorado, United States
• University of Florida - Gainesville — Gainesville, Florida, United States
• Ann & Robert H. Lurie Children's Hospital of Chicago, Pediatrics — Chicago, Illinois, United States
• Massachusetts General Hospital, Department of Pediatrics — Boston, Massachusetts, United States
• Oregon Health and Science University Department of Molecular and Medical Genetics — Portland, Oregon, United States
• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
• University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh — Pittsburgh, Pennsylvania, United States
• Medical University of South Carolina, Pediatrics — Charleston, South Carolina, United States
• Division of Medical Genetics-Pediatrics, Vanderbilt University Medical Center — Nashville, Tennessee, United States
• UT Southwestern Medical Center — Dallas, Texas, United States
• McGovern Medical School/Memorial Hermann Hospital — Houston, Texas, United States
• MAGIC Clinic — Calgary, Alberta, Canada
• Hamilton Health Sciences Corporation — Hamilton, Ontario, Canada
• Children's Hospital of Eastern Ontario — Ottawa, Ontario, Canada
• University Health Network — Toronto, Ontario, Canada
• Medical Genetics and Laboratory Diagnostics Center — Tbilisi, Georgia
• Gazi Üniversitesi Hastanesi — Yenimahalle, Ankara, Turkey (Türkiye)
• Dokuz Eylül Üniversitesi Araştırma ve Uygulama Hastanesi — Balçova, İzmir, Turkey (Türkiye)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.